Therapeutics Acquisition Corp. (TXAC) Prices Upsized $118M IPO
Therapeutics Acquisition Corp. (TXAC), announced the pricing of their upsized $118 million SPAC IPO this afternoon and the shares are currently trading under the symbol Nasdaq: TXAC.
Therapeutics Acquisition Corp. is being sponsored by RA Capital Management, L.P., and is being led by Chairman and CEO Peter Kolchinsky PhD, and CFO Matthew Hammond PhD.
Total SPAC deal count for 2020 year-to-date is now 39 with $12.319 billion in gross proceeds raised. The offering is anticipated to close on Friday, July 10, 2020.
Jefferies LLC acted as sole book-running manager for the offering. Goodwin Procter LLP and White & Case LLP were Issuer’s Counsel and Underwriter’s Counsel, respectively. WithumSmith+Brown, PC, acted as auditor.